  A total of 156 patients ( age range 1.3-18.0 years , median 13.2 years; 91 ( 58.3 %) male) with newly diagnosed CML ( N = 146 chronic phase ( CML-CP) , N = 3 accelerated phase ( CML-AP) , N = 7 blastic phase ( CML-BP)) received imatinib up-front ( 300 , 400 , 500 mg/m